Compare DAL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAL | NTRA |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2B | 32.9B |
| IPO Year | N/A | 2015 |
| Metric | DAL | NTRA |
|---|---|---|
| Price | $70.03 | $226.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 15 |
| Target Price | $79.06 | ★ $249.53 |
| AVG Volume (30 Days) | ★ 8.3M | 1.1M |
| Earning Date | 01-13-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | ★ 43.72 | N/A |
| EPS | ★ 7.66 | N/A |
| Revenue | ★ $63,364,000,000.00 | $2,116,676,000.00 |
| Revenue This Year | N/A | $33.77 |
| Revenue Next Year | $5.64 | $16.92 |
| P/E Ratio | $9.02 | ★ N/A |
| Revenue Growth | 2.79 | ★ 38.17 |
| 52 Week Low | $34.74 | $125.38 |
| 52 Week High | $73.16 | $256.36 |
| Indicator | DAL | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 40.55 |
| Support Level | $64.47 | $229.14 |
| Resistance Level | $68.30 | $235.62 |
| Average True Range (ATR) | 2.15 | 7.88 |
| MACD | -0.12 | -1.80 |
| Stochastic Oscillator | 81.12 | 11.44 |
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.